Developer docs
API playgroundTry for free, no card

Search company profiles

RadioMedix

Full company profile

uuid00006bi

Namestring
RadioMedix
Legal namestring
RadioMedix, Inc.
Websiteurl
radiomedix.com
Company typeenum
Private
Founded yearint
2006
Descriptiontext

RadioMedix is a clinical-stage biotechnology company founded in 2006 and headquartered in Houston, Texas, that develops targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Its core technology platform centers on alpha- and beta-emitting isotopes — including Lead-212 (Pb-212), Actinium-225 (Ac-225), Lutetium-177 (Lu-177), Lead-203 (Pb-203), and Gallium-68 (Ga-68) — engineered into both PET imaging diagnostics and targeted alpha therapy (TAT) agents. The flagship therapeutic asset, AlphaMedix (212Pb-DOTAMTATE), is a Pb-212-labeled somatostatin analogue for neuroendocrine tumors that received FDA Breakthrough Therapy Designation in February 2024 and demonstrated a 62.5% objective response rate in Phase 2. The diagnostic portfolio includes FDA-approved Ga-68 PSMA-11 (Gozetotide) for prostate cancer imaging, plus investigational 68Ga-RMX-VH and 203Pb-RMX-VH-PIB companion diagnostics targeting LDLR in glioblastoma multiforme and pancreatic ductal adenocarcinoma. The proprietary RAHA-100 bench-top Pb-212 generator, launched in June 2025, enables on-demand isotope production for both internal pipeline use and external distribution.

The company operates a vertically integrated model combining early-stage R&D, clinical development, and cGMP commercial-scale manufacturing at the 27,500 sq. ft. SPICA Center facility in Humble, Texas, which houses six aseptic clean rooms and full 21 CFR 211 compliance. Revenue is generated through three principal streams: (1) licensing and milestone/royalty payments from pharmaceutical partners — most notably the September 2024 exclusive global licensing agreement with Sanofi for AlphaMedix (€100M upfront plus up to €220M in sales milestones and tiered royalties); (2) CDMO/contract manufacturing services for biopharma and academic clients at the SPICA Center; and (3) direct commercialization of FDA-approved diagnostic products such as Ga-68 PSMA-11. To secure upstream supply, RadioMedix has executed dual five-year Thorium-228 supply agreements with Thor Medical ASA and Van Overeem Nuclear B.V. (announced December 2025). The company is founder-led by Dr. Ebrahim Delpassand (former MD Anderson chief of clinical nuclear medicine), with a team of approximately 40 employees, and has previously divested non-core assets such as the 225Ac-PSMA I&T program to Fusion Pharmaceuticals.

Short descriptiontext

RadioMedix is a Houston-based clinical-stage biotechnology company developing targeted radiopharmaceuticals (Pb-212, Ga-68, Ac-225) for cancer diagnosis and therapy, with integrated cGMP manufacturing at its SPICA Center and a $100M+ licensing deal with Sanofi for its lead AlphaMedix asset.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersHouston, United States
HQ citystring
Houston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
targeted radiopharmaceuticals, alpha emitter therapy, cancer diagnostic imaging, radiopharmaceutical CDMO, isotope generator technology
Industry4 codes
PRIMARYHLAIAGAB
Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAIAGAC
Theranostic Radiopharmaceutical Platforms (Paired Dx/Tx)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAIAGAF
Radiopharmaceutical CDMO & Manufacturing (GMP Fill-Finish)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAIAGAD
Radioisotope Production (Reactor/Cyclotron/Gamma)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
NAICS code2 codes
  • Pharmaceutical and Medicine Manufacturing3254
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code2 codes
  • Pharmaceutical Preparations2834
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Radiopharmaceuticals / Targeted Radiotherapy
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Licensing and Milestone Payments
TypeLicensing Royalties
Description

RadioMedix licenses its proprietary technologies and drug candidates to major pharmaceutical partners. Received €100 million upfront payment from Sanofi for AlphaMedix licensing, plus up to €220 million in sales milestones and tiered royalties. This represents the primary revenue stream for the company.

radiomedix.com
2CDMO/Contract Manufacturing Services
TypeProfessional Services
Description

RadioMedix provides contract manufacturing and development services for radiopharmaceuticals to academic and industrial partners through its SPICA Center facility. Services include radiochemistry solutions, analytical method development, process validation, and GMP manufacturing.

radiomedix.com
3Product Sales
TypeOne Time License
Description

Direct commercialization of FDA-approved diagnostic radiopharmaceuticals including Ga-68 PSMA-11 (Gallium Ga 68 Gozetotide Injection) for prostate cancer imaging.

radiomedix.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Supply Chain, Infrastructure, Marketing or Sales, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1RAHA-100
Description

Proprietary bench top generator technology designed to streamline the production of on-demand supply of Lead-212 (212Pb) isotope for research and clinical development of targeted Alpha Therapy radiopharmaceuticals.

radiomedix.com
+1 more record
Core offering1 text field

RadioMedix develops and commercializes targeted radiopharmaceuticals for oncology, including targeted alpha therapy (TAT) agents such as AlphaMedix (212Pb-DOTAMTATE) for neuroendocrine tumors, the proprietary RAHA-100 bench top 212Pb generator for on-demand isotope production, and PET diagnostic imaging agents such as FDA-approved Ga-68 PSMA-11 for prostate cancer. The company also provides CDMO/contract manufacturing services for radiopharmaceuticals through its cGMP SPICA Center facility.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • AlphaMedix demonstrated 62.5% objective response rate (ORR) in Phase 2 trials for neuroendocrine tumors, more than twice the current standard of care
+2 more records
Product overview1 text field

RadioMedix is a clinical-stage biotechnology company developing targeted radiopharmaceuticals for cancer diagnosis and therapy. The company operates from a unified product portfolio centered on alpha-emitter based therapies (Targeted Alpha Therapy) and diagnostic imaging agents. The core therapeutic product is AlphaMedix (212Pb-DOTAMTATE), a lead-212 labeled somatostatin analogue for neuroendocrine tumors. Supporting the pipeline is RAHA-100, a proprietary bench top 212Pb generator enabling on-demand isotope production. The diagnostic portfolio includes Ga-68 PSMA-11 (FDA-approved), 68Ga-RMX-VH, and 203Pb-RMX-VH-PIB for various cancer imaging applications. Manufacturing capabilities are anchored by the SPICA Center, a 27,500 sq. ft. cGMP facility supporting both clinical and commercial-scale production. The company also licensed DetectNet to Curium and previously sold its 225Ac-PSMA I&T program to Fusion Pharmaceuticals.

Product and service6 records
1AlphaMedix (212Pb-DOTAMTATE)
CategoryTherapeutic Radiopharmaceutical
Description

A lead-212 (212Pb) labeled somatostatin analogue targeted alpha therapy (TAT) agent for the treatment of metastatic or inoperable somatostatin-expressing neuroendocrine tumors. Uses 212Pb as an in vivo generator of alpha particles for precise tumor cell destruction. Demonstrated 62.5% objective response rate in Phase 2 trials.

2RAHA-100 (212Pb Generator)
CategoryPlatform / Manufacturing Technology
Description

A proprietary bench top generator technology for streamlined on-demand production of Lead-212 (212Pb) isotope for targeted alpha therapy research and clinical development. Features fully automated synthesis, multiple high-activity modular columns, downstream purification steps, and production yield greater than 65% from elution to formulation.

3Ga-68 PSMA-11 (Gozetotide)
CategoryFDA-Approved Diagnostic Radiopharmaceutical
Description

An FDA-approved radioactive diagnostic agent for PET imaging of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer. Indicated for patients with suspected metastasis who are candidates for initial definitive therapy and those with suspected recurrence based on elevated PSA. Supplied as clear, colorless solution at 18.5 MBq/mL to 185 MBq/mL.

468Ga-RMX-VH
CategoryDiagnostic Radiopharmaceutical
Description

A PET imaging agent targeting the Low-Density Lipoprotein Receptor (LDLR) for diagnostic imaging of Glioblastoma Multiforme (GBM) and Pancreatic Ductal Adenocarcinoma (PDAC). Serves as companion diagnostic for future targeted alpha therapy.

5203Pb-RMX-VH-PIB
CategoryDiagnostic Radiopharmaceutical
Description

A diagnostic imaging agent targeting LDLR for PET imaging of Glioblastoma Multiforme and Pancreatic Ductal Adenocarcinoma. Demonstrated significant tumor accumulation and ability to cross the blood-brain barrier in preclinical studies. Serves as companion diagnostic for future targeted alpha therapy.

6SPICA Center Contract Manufacturing (CDMO) Services
CategoryManufacturing Services / CDMO
Description

Contract Development and Manufacturing Organization (CDMO) services for radiopharmaceuticals at the SPICA Center facility, including radiochemistry solutions, analytical method development, process validation, and GMP manufacturing from clinical to commercial scale. Offered to academic and industrial partners.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
1Van Overeem Nuclear B.V.
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-12-12
Description

Five-year agreement for supply of Thorium-228 (228Th). Expands RadioMedix's upstream isotope supply network to ensure reliable 212Pb production for targeted alpha therapy development and manufacturing.

radiomedix.com
2Thor Medical ASA
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-12-04
Description

Five-year supply agreement for Thorium-228 (Th-228) starting in 2026. Thor Medical supplies the precursor for RadioMedix's production of Lead-212 (Pb-212) to support their therapeutic pipeline and RAHA-100 generator platform.

radiomedix.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-09-11
Description

Co-development and licensing agreement for theranostic agents including 68Ga-RMX-VH and 203Pb-RMX-VH-PIB for glioblastoma multiforme and pancreatic ductal adenocarcinoma. Vect-Horus provides molecular vector expertise for targeted delivery; RadioMedix handles radiopharmaceutical development and manufacturing.

Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-06-12
Description

Licensed DetectNet diagnostic imaging asset to Curium for distribution. RadioMedix retains development capabilities while Curium handles commercial distribution.

Strategic tierCore/FlagshipTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2024-09-12
Description

Exclusive licensing agreement for AlphaMedix (212Pb-DOTAMTATE) targeting rare neuroendocrine tumors. RadioMedix and Orano Med received €100 million upfront payment and up to €220 million in sales milestones plus tiered royalties. Sanofi responsible for global commercialization while Orano Med handles manufacturing.

Strategic tierMinorTypeOthersAnnounced on2023-02-15
Description

Acquisition of RadioMedix's 225Ac-PSMA I&T program, a targeted alpha therapy for metastatic castration resistant prostate cancer. Asset sale transaction.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Direct co-developer of AlphaMedix (212Pb-DOTAMTATE) and the lead producer of Pb-212 for targeted alpha therapy. RadioMedix and Orano Med jointly developed AlphaMedix and share the Sanofi licensing economics, making them the most directly comparable peer in the Pb-212 space.

TypeBroad incumbent
Description

Established radioligand therapy leader with Lutathera (177Lu-DOTATATE for NETs) and Pluvicto (177Lu-PSMA-617 for prostate cancer). Competes head-to-head with AlphaMedix in neuroendocrine tumors and with RadioMedix's PSMA diagnostic franchise; broadly incumbent across the radiopharmaceutical value chain.

TypeDirect peer
Description

Radiopharmaceutical company specializing in diagnostic imaging agents including PYLARIFY (18F-DCFPyL PSMA PET tracer), directly comparable to RadioMedix's Ga-68 PSMA-11 diagnostic and broader nuclear medicine imaging portfolio.

TypeDirect peer
Description

Commercial-stage radiopharma company with Illuccix (Ga-68 PSMA-11 PET tracer) directly competing with RadioMedix's FDA-approved Gozetotide in prostate cancer imaging, plus an expanding therapeutic pipeline in targeted radiation.

TypeDirect peer
Description

Global radiopharmaceutical company that licensed RadioMedix's DetectNet diagnostic imaging asset. Direct peer in nuclear medicine diagnostics distribution and a commercial partner, with overlapping product portfolios in PET imaging agents.

TypeBroad incumbent
Description

Broad incumbent with Xofigo (223Ra, alpha emitter for prostate cancer bone metastases) and an expanding radioligand therapy pipeline via Algeta legacy and Noria/Pepaxto acquisitions; competes with RadioMedix in the alpha-emitter therapy space.

TypeDirect peer
Description

Targeted alpha therapy developer that acquired RadioMedix's 225Ac-PSMA I&T program in 2023 and was subsequently acquired by AstraZeneca. Comparable as an alpha-emitter platform company with actinium-225-based programs targeting similar oncology indications.

TypeDirect peer
Description

Radiopharmaceutical platform company producing medical radioisotopes (including Lu-177) and developing targeted radiopharmaceutical therapies. Comparable as a vertically integrated isotope producer and radiopharma developer serving similar customer segments.

TypeDirect peer
Description

Radioligand therapy company developing 177Lu-based PSMA and somatostatin therapies, acquired by Eli Lilly. Directly comparable to RadioMedix's AlphaMedix franchise in the targeted radionuclide therapy space for prostate and neuroendocrine tumors.

TypeBroad incumbent
Description

Global diagnostic imaging company with a portfolio of contrast agents and nuclear medicine products. Broad incumbent serving overlapping healthcare provider customers with diagnostic imaging solutions, though not directly specializing in radiopharmaceuticals.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

RadioMedix

Radiopharmaceuticals / Targeted Radiotherapyradiomedix.com

RadioMedix is a Houston-based clinical-stage biotechnology company developing targeted radiopharmaceuticals (Pb-212, Ga-68, Ac-225) for cancer diagnosis and therapy, with integrated cGMP manufacturing at its SPICA Center and a $100M+ licensing deal with Sanofi for its lead AlphaMedix asset.

What RadioMedix does

RadioMedix is a clinical-stage biotechnology company founded in 2006 and headquartered in Houston, Texas, that develops targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Its core technology platform centers on alpha- and beta-emitting isotopes — including Lead-212 (Pb-212), Actinium-225 (Ac-225), Lutetium-177 (Lu-177), Lead-203 (Pb-203), and Gallium-68 (Ga-68) — engineered into both PET imaging diagnostics and targeted alpha therapy (TAT) agents. The flagship therapeutic asset, AlphaMedix (212Pb-DOTAMTATE), is a Pb-212-labeled somatostatin analogue for neuroendocrine tumors that received FDA Breakthrough Therapy Designation in February 2024 and demonstrated a 62.5% objective response rate in Phase 2. The diagnostic portfolio includes FDA-approved Ga-68 PSMA-11 (Gozetotide) for prostate cancer imaging, plus investigational 68Ga-RMX-VH and 203Pb-RMX-VH-PIB companion diagnostics targeting LDLR in glioblastoma multiforme and pancreatic ductal adenocarcinoma. The proprietary RAHA-100 bench-top Pb-212 generator, launched in June 2025, enables on-demand isotope production for both internal pipeline use and external distribution.

The company operates a vertically integrated model combining early-stage R&D, clinical development, and cGMP commercial-scale manufacturing at the 27,500 sq. ft. SPICA Center facility in Humble, Texas, which houses six aseptic clean rooms and full 21 CFR 211 compliance. Revenue is generated through three principal streams: (1) licensing and milestone/royalty payments from pharmaceutical partners — most notably the September 2024 exclusive global licensing agreement with Sanofi for AlphaMedix (€100M upfront plus up to €220M in sales milestones and tiered royalties); (2) CDMO/contract manufacturing services for biopharma and academic clients at the SPICA Center; and (3) direct commercialization of FDA-approved diagnostic products such as Ga-68 PSMA-11. To secure upstream supply, RadioMedix has executed dual five-year Thorium-228 supply agreements with Thor Medical ASA and Van Overeem Nuclear B.V. (announced December 2025). The company is founder-led by Dr. Ebrahim Delpassand (former MD Anderson chief of clinical nuclear medicine), with a team of approximately 40 employees, and has previously divested non-core assets such as the 225Ac-PSMA I&T program to Fusion Pharmaceuticals.

RadioMedix firmographics

Firmographics
Name
RadioMedix
Legal name
RadioMedix, Inc.
Website
https://radiomedix.com
Company type
Private
Founded year
2006
Operating status
Operating
Headcount range
11–50 employees
Short description
RadioMedix is a Houston-based clinical-stage biotechnology company developing targeted radiopharmaceuticals (Pb-212, Ga-68, Ac-225) for cancer diagnosis and therapy, with integrated cGMP manufacturing at its SPICA Center and a $100M+ licensing deal with Sanofi for its lead AlphaMedix asset.
Ownership category
akta.pro rank

RadioMedix industry classification

Industry
Product category
Radiopharmaceuticals / Targeted Radiotherapy
NAICS
Pharmaceutical and Medicine Manufacturing (3254), In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
Pharmaceutical Preparations (2834), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAIAGAB
Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAIAGAC
Theranostic Radiopharmaceutical Platforms (Paired Dx/Tx)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAIAGAF
Radiopharmaceutical CDMO & Manufacturing (GMP Fill-Finish)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAIAGAD
Radioisotope Production (Reactor/Cyclotron/Gamma)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine

Keywords

  • Targeted radiopharmaceuticals
  • Alpha emitter therapy
  • Cancer diagnostic imaging
  • Radiopharmaceutical CDMO
  • Isotope generator technology

Where RadioMedix is headquartered

Location

Headquarters

HQ city
Houston
HQ country
United States
HQ region
North America

Offices2 records

Markets served

RadioMedix business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Supply Chain, Infrastructure, Marketing or Sales, Operations

Revenue model

  1. Licensing and Milestone Payments: RadioMedix licenses its proprietary technologies and drug candidates to major pharmaceutical partners. Received €100 million upfront payment from Sanofi for AlphaMedix licensing, plus up to €220 million in sales milestones and tiered royalties. This represents the primary revenue stream for the company.
  2. CDMO/Contract Manufacturing Services: RadioMedix provides contract manufacturing and development services for radiopharmaceuticals to academic and industrial partners through its SPICA Center facility. Services include radiochemistry solutions, analytical method development, process validation, and GMP manufacturing.
  3. Product Sales: Direct commercialization of FDA-approved diagnostic radiopharmaceuticals including Ga-68 PSMA-11 (Gallium Ga 68 Gozetotide Injection) for prostate cancer imaging.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels7 records

RadioMedix product offering

Product offering

Core offering

RadioMedix develops and commercializes targeted radiopharmaceuticals for oncology, including targeted alpha therapy (TAT) agents such as AlphaMedix (212Pb-DOTAMTATE) for neuroendocrine tumors, the proprietary RAHA-100 bench top 212Pb generator for on-demand isotope production, and PET diagnostic imaging agents such as FDA-approved Ga-68 PSMA-11 for prostate cancer. The company also provides CDMO/contract manufacturing services for radiopharmaceuticals through its cGMP SPICA Center facility.

Product overview

RadioMedix is a clinical-stage biotechnology company developing targeted radiopharmaceuticals for cancer diagnosis and therapy. The company operates from a unified product portfolio centered on alpha-emitter based therapies (Targeted Alpha Therapy) and diagnostic imaging agents. The core therapeutic product is AlphaMedix (212Pb-DOTAMTATE), a lead-212 labeled somatostatin analogue for neuroendocrine tumors. Supporting the pipeline is RAHA-100, a proprietary bench top 212Pb generator enabling on-demand isotope production. The diagnostic portfolio includes Ga-68 PSMA-11 (FDA-approved), 68Ga-RMX-VH, and 203Pb-RMX-VH-PIB for various cancer imaging applications. Manufacturing capabilities are anchored by the SPICA Center, a 27,500 sq. ft. cGMP facility supporting both clinical and commercial-scale production. The company also licensed DetectNet to Curium and previously sold its 225Ac-PSMA I&T program to Fusion Pharmaceuticals.

Differentiator

Problem solved

Functional benefit

Brands

  • RAHA-100: Proprietary bench top generator technology designed to streamline the production of on-demand supply of Lead-212 (212Pb) isotope for research and clinical development of targeted Alpha Therapy radiopharmaceuticals.
  • AlphaMedix

Products and services

  • AlphaMedix (212Pb-DOTAMTATE) A lead-212 (212Pb) labeled somatostatin analogue targeted alpha therapy (TAT) agent for the treatment of metastatic or inoperable somatostatin-expressing neuroendocrine tumors. Uses 212Pb as an in vivo generator of alpha particles for precise tumor cell destruction. Demonstrated 62.5% objective response rate in Phase 2 trials.
  • RAHA-100 (212Pb Generator) A proprietary bench top generator technology for streamlined on-demand production of Lead-212 (212Pb) isotope for targeted alpha therapy research and clinical development. Features fully automated synthesis, multiple high-activity modular columns, downstream purification steps, and production yield greater than 65% from elution to formulation.
  • Ga-68 PSMA-11 (Gozetotide) An FDA-approved radioactive diagnostic agent for PET imaging of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer. Indicated for patients with suspected metastasis who are candidates for initial definitive therapy and those with suspected recurrence based on elevated PSA. Supplied as clear, colorless solution at 18.5 MBq/mL to 185 MBq/mL.
  • 68Ga-RMX-VH A PET imaging agent targeting the Low-Density Lipoprotein Receptor (LDLR) for diagnostic imaging of Glioblastoma Multiforme (GBM) and Pancreatic Ductal Adenocarcinoma (PDAC). Serves as companion diagnostic for future targeted alpha therapy.
  • 203Pb-RMX-VH-PIB A diagnostic imaging agent targeting LDLR for PET imaging of Glioblastoma Multiforme and Pancreatic Ductal Adenocarcinoma. Demonstrated significant tumor accumulation and ability to cross the blood-brain barrier in preclinical studies. Serves as companion diagnostic for future targeted alpha therapy.
  • SPICA Center Contract Manufacturing (CDMO) Services Contract Development and Manufacturing Organization (CDMO) services for radiopharmaceuticals at the SPICA Center facility, including radiochemistry solutions, analytical method development, process validation, and GMP manufacturing from clinical to commercial scale. Offered to academic and industrial partners.

Quantifiable outcome

  • AlphaMedix demonstrated 62.5% objective response rate (ORR) in Phase 2 trials for neuroendocrine tumors, more than twice the current standard of care
  • +2 more outcomes

Companies that use RadioMedix

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles3 records

RadioMedix technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

RadioMedix partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core, minor and core/flagship.

  • Van Overeem Nuclear B.V.coreTechnology or Integration · 12 December 2025Five-year agreement for supply of Thorium-228 (228Th). Expands RadioMedix's upstream isotope supply network to ensure reliable 212Pb production for targeted alpha therapy development and manufacturing.
  • Thor Medical ASAcoreTechnology or Integration · 4 December 2025Five-year supply agreement for Thorium-228 (Th-228) starting in 2026. Thor Medical supplies the precursor for RadioMedix's production of Lead-212 (Pb-212) to support their therapeutic pipeline and RAHA-100 generator platform.
  • Vect-HoruscoreStrategic or Co-development Partner · 11 September 2025Co-development and licensing agreement for theranostic agents including 68Ga-RMX-VH and 203Pb-RMX-VH-PIB for glioblastoma multiforme and pancreatic ductal adenocarcinoma. Vect-Horus provides molecular vector expertise for targeted delivery; RadioMedix handles radiopharmaceutical development and manufacturing.
  • Curium PharmaminorChannel Partner/ Reseller/ Distributor · 12 June 2025Licensed DetectNet diagnostic imaging asset to Curium for distribution. RadioMedix retains development capabilities while Curium handles commercial distribution.
  • Sanoficore/flagshipOEM/ Whitelabel/ Licensing Partner · 12 September 2024Exclusive licensing agreement for AlphaMedix (212Pb-DOTAMTATE) targeting rare neuroendocrine tumors. RadioMedix and Orano Med received €100 million upfront payment and up to €220 million in sales milestones plus tiered royalties. Sanofi responsible for global commercialization while Orano Med handles manufacturing.
  • Fusion Pharmaceuticals Inc.minorOthers · 15 February 2023Acquisition of RadioMedix's 225Ac-PSMA I&T program, a targeted alpha therapy for metastatic castration resistant prostate cancer. Asset sale transaction.

Scale indicators6 records

Recent moves8 records

Expansion highlights6 records

RadioMedix competitors and assessment

Company assessment

Direct peers

  • Orano Med: Direct co-developer of AlphaMedix (212Pb-DOTAMTATE) and the lead producer of Pb-212 for targeted alpha therapy. RadioMedix and Orano Med jointly developed AlphaMedix and share the Sanofi licensing economics, making them the most directly comparable peer in the Pb-212 space.
  • Lantheus Holdings: Radiopharmaceutical company specializing in diagnostic imaging agents including PYLARIFY (18F-DCFPyL PSMA PET tracer), directly comparable to RadioMedix's Ga-68 PSMA-11 diagnostic and broader nuclear medicine imaging portfolio.
  • Telix Pharmaceuticals: Commercial-stage radiopharma company with Illuccix (Ga-68 PSMA-11 PET tracer) directly competing with RadioMedix's FDA-approved Gozetotide in prostate cancer imaging, plus an expanding therapeutic pipeline in targeted radiation.
  • Curium Pharma: Global radiopharmaceutical company that licensed RadioMedix's DetectNet diagnostic imaging asset. Direct peer in nuclear medicine diagnostics distribution and a commercial partner, with overlapping product portfolios in PET imaging agents.
  • Fusion Pharmaceuticals: Targeted alpha therapy developer that acquired RadioMedix's 225Ac-PSMA I&T program in 2023 and was subsequently acquired by AstraZeneca. Comparable as an alpha-emitter platform company with actinium-225-based programs targeting similar oncology indications.
  • ITM Isotope Technologies Munich: Radiopharmaceutical platform company producing medical radioisotopes (including Lu-177) and developing targeted radiopharmaceutical therapies. Comparable as a vertically integrated isotope producer and radiopharma developer serving similar customer segments.
  • Point Biopharma: Radioligand therapy company developing 177Lu-based PSMA and somatostatin therapies, acquired by Eli Lilly. Directly comparable to RadioMedix's AlphaMedix franchise in the targeted radionuclide therapy space for prostate and neuroendocrine tumors.

Broad incumbents

  • Novartis: Established radioligand therapy leader with Lutathera (177Lu-DOTATATE for NETs) and Pluvicto (177Lu-PSMA-617 for prostate cancer). Competes head-to-head with AlphaMedix in neuroendocrine tumors and with RadioMedix's PSMA diagnostic franchise; broadly incumbent across the radiopharmaceutical value chain.
  • Bayer (Radiopharmaceuticals): Broad incumbent with Xofigo (223Ra, alpha emitter for prostate cancer bone metastases) and an expanding radioligand therapy pipeline via Algeta legacy and Noria/Pepaxto acquisitions; competes with RadioMedix in the alpha-emitter therapy space.
  • Bracco Imaging: Global diagnostic imaging company with a portfolio of contrast agents and nuclear medicine products. Broad incumbent serving overlapping healthcare provider customers with diagnostic imaging solutions, though not directly specializing in radiopharmaceuticals.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

RadioMedix social profiles

Digital presence

RadioMedix compliance and trust

Trust signal

Compliance3 records

RadioMedix financial estimates

Financial estimate

Revenue estimate

Valuation estimate

RadioMedix leadership team

Management profile

Number of profiles

Profiles7 records

RadioMedix funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

RadioMedix M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about RadioMedix

What does RadioMedix do?

RadioMedix develops and commercializes targeted radiopharmaceuticals for oncology, including targeted alpha therapy (TAT) agents such as AlphaMedix (212Pb-DOTAMTATE) for neuroendocrine tumors, the proprietary RAHA-100 bench top 212Pb generator for on-demand isotope production, and PET diagnostic imaging agents such as FDA-approved Ga-68 PSMA-11 for prostate cancer. The company also provides CDMO/contract manufacturing services for radiopharmaceuticals through its cGMP SPICA Center facility.

Is RadioMedix a public or private company?

RadioMedix is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was RadioMedix founded?

RadioMedix was founded in 2006. It employs 11 to 50 people.

Where is RadioMedix based?

RadioMedix is headquartered in Houston, United States, in the North America region.

How does RadioMedix make money?

Three revenue lines are on record. Licensing and Milestone Payments are the primary driver. The others are CDMO/Contract Manufacturing Services and product Sales.

Who are RadioMedix's main competitors?

Direct peers on record are Orano Med, Lantheus Holdings, Telix Pharmaceuticals, Curium Pharma, Fusion Pharmaceuticals, ITM Isotope Technologies Munich and Point Biopharma. Broad incumbents are Novartis, Bayer (Radiopharmaceuticals) and Bracco Imaging.

Does RadioMedix have an API?

No public API is recorded for RadioMedix.

What industry is RadioMedix in?

RadioMedix's product category is Radiopharmaceuticals / Targeted Radiotherapy. Its primary akta.pro industry code is HLAIAGAB, Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy), with a secondary code of HLAIAGAC, Theranostic Radiopharmaceutical Platforms (Paired Dx/Tx). Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
OncLiveFDA Approves Copper Cu 64 Dotatate Injection for Somatostatin Receptor–Positive NETsThe FDA has approved copper Cu 64 dotatate injection (Detectnet) for the localization of somatostatin receptor–positive neuroendocrine tumors, according to an announcement from RadioMedix Inc. and Curium Pharma. The diagnostic agent is anticipated to launch immediately across the United States via nuclear pharmacies and imaging centers. Clinical studies demonstrated high sensitivity and specificity in detecting NETs, with a favorable safety profile reported.GlobeNewswireRadioMedix Appoints Brian A. Markison to Board of DirectorsRadioMedix, Inc., a clinical-stage biotechnology company focused on targeted radiopharmaceuticals for cancer diagnosis and therapy, appointed Brian A. Markison to its board of directors effective July 1, 2026. Markison brings over 40 years of pharmaceutical and radiopharmaceutical industry leadership, including his previous role as CEO of Lantheus Holdings, and experience leading companies through acquisitions by major pharmaceutical firms. The appointment adds the company's second independent director and is intended to support RadioMedix's growth strategy as it advances its cancer theranostic pipeline and scales its manufacturing capabilities.Investing.comRadioMedix appoints Brian Markison to board of directors By Investing.comRadioMedix, Inc. announced the appointment of Brian A. Markison to its board of directors effective July 1, 2026, leveraging his extensive experience in the pharmaceutical industry. Markison previously served as CEO of Lantheus Holdings and held leadership roles at Pfizer, Novartis, and Bristol-Myers Squibb. This strategic hiring aims to bolster RadioMedix's governance as it continues development of targeted radiopharmaceuticals.GlobeNewswireRadioMedix Announces Receiving FDA Approval of its Generic Ga-68 PSMA-11 Radiodiagnostic for Prostate CancerRadioMedix announced that the U.S. Food and Drug Administration (FDA) has approved its generic Ga-68 PSMA-11 radiodiagnostic for prostate cancer imaging. Concurrently, the company successfully completed an FDA inspection of its manufacturing site, The SPICA Center, with no observations noted.BioSpaceRadioMedix Announces Receiving FDA Approval of its Generic Ga-68 PSMA-11 Radiodiagnostic for Prostate CancerRadioMedix announced FDA approval of its Ga-68 PSMA-11 radiopharmaceutical for prostate cancer PET imaging. The approval followed an FDA inspection of its SPICA Center manufacturing site with no Form 483 observations. The company said the approval expands its precision nuclear medicine portfolio.AuntMinnieRadioMedix wins FDA ANDA approval for Ga-68 PSMA-11 PET imaging agentRadioMedix has received FDA approval via an Abbreviated New Drug Application for Ga-68 PSMA-11, a diagnostic radiopharmaceutical used for PET imaging in prostate cancer patients. The approval followed a successful inspection of the company's Spica Center manufacturing facility near Houston, which resulted in no regulatory observations.GlobeNewswireRadioMedix to Present at SNMMI 2026 and Mark 20 Years of Radiopharmaceutical InnovationRadioMedix, Inc. announced its participation at the SNMMI 2026 Annual Meeting in Los Angeles from May 30 to June 2, where its leadership will present on targeted alpha therapy and lead-212 radiopharmaceutical development, including preclinical data on ²¹²Pb-RMX-VH-PKM, a second-generation LDLR-targeting radioconjugate co-developed with Vect-Horus for pancreatic ductal adenocarcinoma. The company's participation marks its 20th anniversary since founding in 2006, highlighting its role in advancing radiopharmaceutical discovery, isotope supply, manufacturing, and clinical development through its SPICA Center facility.BioSpaceRadioMedix to Present at SNMMI 2026 and Mark 20 Years of Radiopharmaceutical InnovationRadioMedix will present at SNMMI 2026 in Los Angeles, with CEO Ebrahim Delpassand and CIO Izabela Tworowska leading sessions on alpha therapy and lead-212 radiopharmaceuticals. The company marks its 20th anniversary, having been founded in 2006, and will share preclinical data on its second-generation LDLR-targeting radioconjugate for pancreatic cancer.European BiotechnologyRadioMedix expands thorium-228 supply for 212PbRadioMedix announced a five-year supply agreement with Van Overeem Nuclear B.V. for Thorium-228, which will support its development of Targeted Alpha Therapy candidates. The deal ensures a reliable isotope supply to facilitate 212Pb production and expand alpha-emitter therapy availability.GlobeNewswireRadioMedix Expands Thorium-228 Supply Network Through New Agreement With Van Overeem Nuclear B.V.RadioMedix has entered into a 5-year agreement with Van Overeem Nuclear B.V. to supply Thorium-228, a key isotope for its targeted alpha therapy (TAT) development. This partnership aims to support RadioMedix's pipeline expansion and manufacturing plans for 212Pb-based radiopharmaceuticals.